Bioglan, Shire Pharmaceuticals Group plc, SkyePharma deal

SKP granted SHP European marketing rights to its Solaraze diclofenac, a non-steroidal anti-inflammatory drug to treat actinic keratosis, for £12.9 million ($18.9 million). SKP is eligible for an additional £2.1 million payment related to launches in certain countries, and is eligible for royalties. European rights to Solaraze previously were held by BGP, which is in receivership, and last year SKP notified BGP that it sought to terminate the deal (see BioCentury, Dec. 3, 2001). ...